CL2024000250A1 - Compuestos de heteroarilo para tratar la enfermedad de huntington - Google Patents
Compuestos de heteroarilo para tratar la enfermedad de huntingtonInfo
- Publication number
- CL2024000250A1 CL2024000250A1 CL2024000250A CL2024000250A CL2024000250A1 CL 2024000250 A1 CL2024000250 A1 CL 2024000250A1 CL 2024000250 A CL2024000250 A CL 2024000250A CL 2024000250 A CL2024000250 A CL 2024000250A CL 2024000250 A1 CL2024000250 A1 CL 2024000250A1
- Authority
- CL
- Chile
- Prior art keywords
- disease
- compounds
- heteroaryl compounds
- compositions
- treating huntington
- Prior art date
Links
- 208000023105 Huntington disease Diseases 0.000 title abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163203761P | 2021-07-30 | 2021-07-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2024000250A1 true CL2024000250A1 (es) | 2024-07-12 |
Family
ID=83149486
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024000250A CL2024000250A1 (es) | 2021-07-30 | 2024-01-29 | Compuestos de heteroarilo para tratar la enfermedad de huntington |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20240336613A1 (enExample) |
| EP (1) | EP4377317A1 (enExample) |
| JP (1) | JP2024528066A (enExample) |
| KR (1) | KR20240054264A (enExample) |
| CN (1) | CN118159539A (enExample) |
| AR (1) | AR126612A1 (enExample) |
| AU (1) | AU2022320725A1 (enExample) |
| CA (1) | CA3227287A1 (enExample) |
| CL (1) | CL2024000250A1 (enExample) |
| CO (1) | CO2024000890A2 (enExample) |
| CR (1) | CR20240043A (enExample) |
| IL (1) | IL310440A (enExample) |
| MX (1) | MX2024001417A (enExample) |
| PE (1) | PE20240929A1 (enExample) |
| TW (1) | TW202321247A (enExample) |
| WO (1) | WO2023009816A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018282154B2 (en) | 2017-06-05 | 2022-04-07 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
| AU2019243048A1 (en) | 2018-03-27 | 2020-10-15 | Ptc Therapeutics, Inc. | Compounds for treating Huntington's disease |
| IL279688B2 (en) | 2018-06-27 | 2025-01-01 | Ptc Therapeutics Inc | Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease |
| BR112020026534A2 (pt) | 2018-06-27 | 2021-03-23 | Ptc Therapeutics, Inc. | Compostos de heteroarila para o tratamento da doença de huntington |
| CN114245794B (zh) | 2019-05-13 | 2024-09-13 | Ptc医疗公司 | 用于治疗亨廷顿氏病的化合物 |
| CN119451674A (zh) * | 2022-06-15 | 2025-02-14 | Ptc医疗公司 | 用于治疗亨廷顿病的杂环和杂芳基化合物 |
| EP4719599A1 (en) | 2023-06-02 | 2026-04-08 | Merck Sharp & Dohme LLC | 5,6 unsaturated bicyclic heterocyles useful as inhibitors of nod-like receptor protein 3 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL279688B2 (en) * | 2018-06-27 | 2025-01-01 | Ptc Therapeutics Inc | Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease |
| WO2020005882A1 (en) * | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| JP2022525417A (ja) * | 2019-03-15 | 2022-05-13 | スカイホーク・セラピューティクス・インコーポレーテッド | 異常スプライシングを修正するための組成物および方法 |
-
2022
- 2022-07-29 WO PCT/US2022/038870 patent/WO2023009816A1/en not_active Ceased
- 2022-07-29 CR CR20240043A patent/CR20240043A/es unknown
- 2022-07-29 AR ARP220102027A patent/AR126612A1/es unknown
- 2022-07-29 AU AU2022320725A patent/AU2022320725A1/en active Pending
- 2022-07-29 JP JP2024505314A patent/JP2024528066A/ja active Pending
- 2022-07-29 US US18/293,349 patent/US20240336613A1/en active Pending
- 2022-07-29 EP EP22761694.3A patent/EP4377317A1/en active Pending
- 2022-07-29 CA CA3227287A patent/CA3227287A1/en active Pending
- 2022-07-29 KR KR1020247003414A patent/KR20240054264A/ko active Pending
- 2022-07-29 PE PE2024000170A patent/PE20240929A1/es unknown
- 2022-07-29 IL IL310440A patent/IL310440A/en unknown
- 2022-07-29 MX MX2024001417A patent/MX2024001417A/es unknown
- 2022-07-29 CN CN202280066651.3A patent/CN118159539A/zh active Pending
- 2022-08-01 TW TW111128808A patent/TW202321247A/zh unknown
-
2024
- 2024-01-29 CL CL2024000250A patent/CL2024000250A1/es unknown
- 2024-01-30 CO CONC2024/0000890A patent/CO2024000890A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3227287A1 (en) | 2023-02-02 |
| TW202321247A (zh) | 2023-06-01 |
| KR20240054264A (ko) | 2024-04-25 |
| US20240336613A1 (en) | 2024-10-10 |
| CR20240043A (es) | 2024-05-22 |
| WO2023009816A1 (en) | 2023-02-02 |
| AR126612A1 (es) | 2023-10-25 |
| MX2024001417A (es) | 2024-05-14 |
| AU2022320725A1 (en) | 2024-02-22 |
| IL310440A (en) | 2024-03-01 |
| JP2024528066A (ja) | 2024-07-26 |
| CO2024000890A2 (es) | 2024-04-29 |
| PE20240929A1 (es) | 2024-04-30 |
| EP4377317A1 (en) | 2024-06-05 |
| CN118159539A (zh) | 2024-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022003434A1 (es) | Compuestos para tratar la enfermedad de huntington (divisional solicitud 202003378) | |
| MX2021013854A (es) | Compuestos para tratar enfermedad de huntington. | |
| MX2019014514A (es) | Compuestos para tratar la enfermedad de huntington. | |
| CO2024000890A2 (es) | Compuestos de heteroarilo para tratar la enfermedad de huntington | |
| CL2024000373A1 (es) | Compuesto inductor de la degradación de plk1 novedoso | |
| EA202092003A1 (ru) | Соединения для лечения болезни гентингтона | |
| CO2019007810A2 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
| MX2020014315A (es) | Compuestos de heteroarilo para tratar la enfermedad de huntington. | |
| MX2022012575A (es) | Compuestos para usarse para tratar la enfermedad de huntington. | |
| CL2020003131A1 (es) | Compuestos de purinona y su uso en el tratamiento del cáncer | |
| UY38403A (es) | Moduladores de la alfa-1 antitripsina | |
| MX391850B (es) | Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington | |
| MX2019012847A (es) | Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer. | |
| ECSP20046463A (es) | Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas | |
| BR112015011760A2 (pt) | composto, uso do composto, e uso de uma composição farmacêutica | |
| CL2020001349A1 (es) | Compuestos, composición y uso de los mismos como moduladores de la expresión de pcsk9. (divisional solicitud 201902574) | |
| CO2021004141A2 (es) | Moduladores de la expresión de pnpla3 | |
| DOP2016000308A (es) | Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer | |
| CL2012002887A1 (es) | Combinación farmacéutica que comprende compuestos derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida, compuestos derivados de n-(2-arilamino)arilsulfonamida y opcionalmente otros agentes farmacéuticos adicionales; kit faramacéutico; método de tratamiento; y su uso para el tratamiento o la profilaxis del cáncer. | |
| UY38228A (es) | Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer | |
| MX2022001535A (es) | Uso de sepiapterina y metabolitos de los mismos para tratar la exposicion a radiacion. | |
| BR112022010702A2 (pt) | Macrociclos para uso no tratamento de doenças | |
| MX2025009815A (es) | Inhibidores de la integrina alfa4beta7 macrociclica | |
| CL2022001523A1 (es) | Compuestos para tratar la disautonomía familiar | |
| BRPI0517032A (pt) | compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades e utilização desses compostos |